Decompensation of Cardiac Hypertrophy: Cellular Mechanisms and Novel Therapeutic Targets

Overview

Journal Physiology (Bethesda)

Specialty Physiology

Date 2007 Feb 10

PMID 17289931

Citations 94

Authors

Abhinav Diwan

Gerald W Dorn 2nd

Affiliations

Soon will be listed here.

Abstract

Cardiac hypertrophy leads to heart failure, and both conditions can ultimately prove lethal. Here, traditional and novel mechanisms relating hypertrophy and heart failure are described at the physiological, cellular, and molecular levels. The rational application of these mechanistic considerations to therapeutics targeting hypertrophy and heart failure is discussed.

Citing Articles

Acute vascular and cardiac effects of lenvatinib in mice.

Kruger D, Pannucci P, Wesley C, Neutel C, Martinet W, De Meyer G Cardiooncology. 2025; 11(1):14.

PMID: 39934897 PMC: 11816767. DOI: 10.1186/s40959-025-00307-8.

The potential roles of exosomes in pathological cardiomyocyte hypertrophy mechanisms and therapy: A review.

Zhang L, Xie F, Zhang F, Lu B Medicine (Baltimore). 2024; 103(17):e37994.

PMID: 38669371 PMC: 11049793. DOI: 10.1097/MD.0000000000037994.

Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.

Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A Circulation. 2023; 149(3):227-250.

PMID: 37961903 PMC: 10842599. DOI: 10.1161/CIRCULATIONAHA.123.066542.

Hypertensive heart disease: risk factors, complications and mechanisms.

Masenga S, Kirabo A Front Cardiovasc Med. 2023; 10:1205475.

PMID: 37342440 PMC: 10277698. DOI: 10.3389/fcvm.2023.1205475.

IL-12α deficiency attenuates pressure overload-induced cardiac inflammation, hypertrophy, dysfunction, and heart failure progression.

Bhattarai U, He X, Xu R, Liu X, Pan L, Sun Y Front Immunol. 2023; 14:1105664.

PMID: 36860846 PMC: 9969090. DOI: 10.3389/fimmu.2023.1105664.